Skip to main content
Clinical Trials/NCT06448429
NCT06448429
Active, Not Recruiting
N/A

Evaluating the Integration of Mental Health Care Into the Treatment of Type 1 Diabetes

Emory University1 site in 1 country80 target enrollmentJune 10, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 1
Sponsor
Emory University
Enrollment
80
Locations
1
Primary Endpoint
Proportion of patients achieving improvements in PHQ-9 score
Status
Active, Not Recruiting
Last Updated
7 months ago

Overview

Brief Summary

This study aims to test the use of an adapted collaborative care model for improving the health outcomes of adults diagnosed with type 1 diabetes (T1D). The duration of the study is 18 months with 4 study survey points. Participants will fill out an online survey regarding their psychosocial health and chronic disease management behaviors once every six months over the 18 months, and individuals who are randomly assigned to the study intervention will also consult at least once with a behavioral health consultant during the first year (active intervention period).

Detailed Description

Type 1 diabetes (T1D) is a lifelong condition that requires consistent monitoring and management, increasing people's risk for common mental disorders that worsen diabetes self-care. Both depression and diabetes can be managed with behavioral interventions, however, they are rarely provided alongside routine diabetes care for people with T1D. In this research study, the investigators aim to evaluate the implementation and effectiveness outcomes of a collaborative care model that uses a Behavioral Health Consultant (BHC) to support lifestyle management among adults with T1D receiving diabetes care at the Grady Diabetes Clinic. A trained clinical research coordinator will screen interested patients seeking treatment at the Grady Diabetes Center and conduct outreach to individuals who have been identified as having T1D within the Grady Diabetes Center's patient population. Participants in the intervention group will engage with a behavioral health consultant (BHC) not affiliated with Grady who will work with them to establish personalized health goals and identify ways to manage stress and promote healthy behaviors as means to support their mental and physical health and meet their set goals (i.e., behavioral activation). Each session will be conducted over the telephone or Zoom and last 30-60 minutes, with the number and frequency of meetings established through discussions between the patient and BHC (typically 2-3 sessions for one year). Checklist and summary case reporting templates will be used to track intervention fidelity. The BHC will also participate in ongoing Zoom calls with the multi-disciplinary T1D clinical team at the Grady Diabetes Center once a month to provide updates on patients' behavioral health plans. Transitioning patients from the active intervention will involve discussions with the care team to ensure continued patient support. In cases of active suicidal ideation, the study team will notify the patient's usual diabetes care provider and the individual will be referred to psychiatric services at Grady.

Registry
clinicaltrials.gov
Start Date
June 10, 2024
End Date
August 1, 2026
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Leslie Johnson

Assistant Professor

Emory University

Eligibility Criteria

Inclusion Criteria

  • Adults (≥18 years) with T1D (based on clinical record diagnosis).

Exclusion Criteria

  • Patients who do not speak English or have reliable telephone access will be excluded. ---
  • Individuals with the presence of severe psychiatric illness (PHQ-9≥20) or active suicidal ideation will also be excluded and referred to specialty care.

Outcomes

Primary Outcomes

Proportion of patients achieving improvements in PHQ-9 score

Time Frame: Baseline and 12 months

The proportion of patients achieving improvements in PHQ-9 score \[PHQ-9\<10\] or a ≥50% PHQ-9 score reduction.

Proportion of patients achieving improvement in HbA1c at end of intervention

Time Frame: Baseline and 12 months

Improvement in HbA1c will be considered as HbA1c\<7 or ≥0.5% HbA1c reduction

Secondary Outcomes

  • Generalized anxiety disorder scale score(Baseline and 12 months)
  • Systolic and diastolic blood pressure (BP) measurements(Baseline and 12 months)
  • Low-density lipoprotein (LDL) cholesterol(Baseline and 12 months)

Study Sites (1)

Loading locations...

Similar Trials